e-learning
resources
Paris 2018
Monday, 17.09.2018
Improving the outcomes of community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia
D. Basille (Amiens, France), R. Thomsen (Aarhus, Denmark), M. Madsen (Aarhus, Denmark), P. Duhaut (Amiens, France), C. Andrejak (Amiens, France), V. Jounieaux (Amiens, France), H. SøRensen (Aarhus, Denmark)
Source:
International Congress 2018 – Improving the outcomes of community-acquired pneumonia
Session:
Improving the outcomes of community-acquired pneumonia
Session type:
Poster Discussion
Number:
2024
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Basille (Amiens, France), R. Thomsen (Aarhus, Denmark), M. Madsen (Aarhus, Denmark), P. Duhaut (Amiens, France), C. Andrejak (Amiens, France), V. Jounieaux (Amiens, France), H. SøRensen (Aarhus, Denmark). Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia. 2024
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia
Source: Eur Respir J 2015; 46: 876-877
Year: 2015
Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia
Source: Eur Respir J 2015; 46: 875-876
Year: 2015
Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia : A cohort study
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Influence of prior nonsteroidal anti-inflammatory steroidal drugs (NSAID) on the presentation and evolution of hospitalized community-acquired pneumonia
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Macrolides as anti-inflammatory agents in CAP
Source: Eur Respir Monogr 2014; 63: 243-255
Year: 2014
Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
A randomized trial of AZD7594 a novel non-steroidal anti-inflammatory drug in asthma patients
Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Year: 2017
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017
Year: 2018
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017
Year: 2018
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Eur Respir J 2010; 36: 1080-1087
Year: 2010
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016
Year: 2017
Update on anti-inflammatory therapy in asthma
Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease
Year: 2012
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Antipyretic effect of dexamethasone in community-acquired pneumonia
Source: Eur Respir J 2015; 46: 570-573
Year: 2015
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006
Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept